CN Patent

CN111888326B — 羟甲唑啉组合物和用于治疗眼障碍的方法

Assigned to RVL Pharmaceuticals Inc · Expires 2023-07-21 · 3y expired

What this patent protects

本公开内容涉及包含羟甲唑啉的组合物和为了长期贮存而稳定羟甲唑啉组合物的方法。本公开内容也涉及包含羟甲唑啉的组合物和治疗受试者的多种与眼睑下垂有关的眼病(诸如上睑下垂)的方法，所述方法包括给所述受试者施用包含羟甲唑啉的组合物。

USPTO Abstract

本公开内容涉及包含羟甲唑啉的组合物和为了长期贮存而稳定羟甲唑啉组合物的方法。本公开内容也涉及包含羟甲唑啉的组合物和治疗受试者的多种与眼睑下垂有关的眼病(诸如上睑下垂)的方法，所述方法包括给所述受试者施用包含羟甲唑啉的组合物。

Drugs covered by this patent

oxymetazoline-hydrochloride (OXYMETAZOLINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN111888326B
Jurisdiction: CN
Classification: —
Expires: 2023-07-21
Drug substance claim: No
Drug product claim: No
Assignee: RVL Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.